Lipoprotein transport system Lol may be a selective target for Gram-negative bacteria

Authors:

Abstract
In a recent study published in Nature, Munoz et al. have developed the novel antibiotic, lolamicin, which targets the Gram-negative bacterial outer membrane lipoprotein transporter LolCDE.(Figure 1)This compound demonstrated efficacy in multiple murine models of acute pneumonia and sepsis, effectively preventing Clostridium difficile infection, as well as maintaining gut microbial stability. [1] In recent years, the World Health Organization has been conducting research on antibiotics and drug-resistant bacteria. Multidrug resistance in Gram-negative bacterial infections poses a significant threat with a high risk of morbidity and mortality. Traditionally, Gram-negative infections (especially their multidrug-resistant strains) have been difficult to treat, mainly due to the significant disadvantages of existing treatment options, such as aminoglycosides and glycocycline, including non-negligible toxicity and possible suboptimal pharmacokinetics at certain infection sites. Consequently, pharmaceutical researchers are eager to discover alternative antibacterial drugs and protocols. While a variety of antibiotics are approved for Gram-negative infection treatment, maintaining the gut microbiome homeostasis after administration remains a challenge. The unique permeability outer membrane structure of Gram-negative bacteria is pivotal in their antibiotic resistance mechanisms. These may involve enzyme inactivation, efflux pumps, porin protein mutations, and target site modifications.Effective targets can be identified through pathways such as efflux pump inhibition, membrane protein modification, lipopolysaccharide synthesis, etc., including recently discovered macrocyclic peptides antibiotics to target lipopolysaccharide synthesis. [2,3] Presently, as antibiotic resistance continues to rise, the arsenal of effective antibiotics for Gram-negative bacteria is depleting. It is an urgent need for new antibiotics. Researchers including Munoz suggested that the development of a specific antibiotic without affecting the microbiome should identify its unique target, discriminating it from beneficial commensals. [1] Bacterial lipoproteins, a vital component of bacterial cell membranes, is directly involved in the pathogenic mechanisms of numerous infectious agents and serves as an immunostimulatory factor facilitating inflammatory responses, where the lipid transport process of most lipoproteins necessitates the assistance of Lol transport system. It was noted that Lol lipoprotein transport system was essential for bacterial survival in various environments, associated with physiological and pathological mechanisms of Gram-negative bacteria, such as nutrition, stress response, virulence.[4] The correct localization of lipoprotein in cells is the basis for their physiological function, which depends on the normal operation of the lipoprotein transport system. Lipoprotein synthesis implements the physiological process of bacteria, which makes the lipoprotein transport system necessary for bacterial survival, but there are still problems such as unclear mechanisms of lipoprotein secretion and surface display. Concurrently, during the transportation of lipoproteins, the signal secreted by the N-terminus of mature outer membrane lipoproteins is initially recognized by the LolCDE complex, which participates in transmembrane protein transfer. This transport pathway influences bacterial membrane stress response and further impacts outer membrane synthesis and cell survival.[5] Overuse of antibiotics leads to drug and even multi-drug resistance, especially non-selective broadspectrum antibiotics, which destroy the homeostasis of symbiotic bacteria in the host while killing the bacteria and exacerbating secondary infections. Based on the structure of two LolCDE inhibitors, pyridinepyrazole [6] and pyridineimidazole [7,8], the researchers designed a novel LolCDE inhibitor-lolamicin. In drug susceptibility studies of clinical strains, low concentrations of lolamicin were found to be active against clinical strains, highlighting its potential against multiple clinical isolates. The development of this promising new targeted antibiotic could effectively reduce the use of some broad-spectrum antibiotics, improve treatment efficiency, and reduce the risk of drug resistance. However, the mechanism remains obscure.Potential targets of lolamicin, as determined through methods such as amino acid sequencing, may include lipoprotien transport proteins like LolC and LolD. Observation by focused microscopy revealed that lolamicin therapy could induce a cell swelling phenotype induced by LspA inhibition with Globomycin. However, this phenotype is distinct from that induced by β-lactams, and similar effects are observed in corresponding LolE mutant strains, indirectly confirming that lolamicin can exert its bactericidal effect through targeting the Lol lipoprotein transporter. To further determine the binding check point of lolamicin, the researchers had explored the antibacterial mode of lolamicin on LolCDE using resistant mutants and molecular modeling technology. Four postulated binding modes -BS1/BS2 and two transient sites TS1/TS2 confirmed that lolamicin competitively inhibits lipoproteins via lipopeptide binding sites, disrupting their normal transport. In terms of its mechanism of action, Lolamicin is able to control the transport of LolA lipoprotein to the outer membrane through competitive binding to LolCDE complex protein, thereby disrupting the normal physiological function of Gram-negative bacteria. This competitive binding pattern may be related to the hydrophobic interaction of nonpolar or aromatic groups, providing a plausible explanation for the reduced efficacy caused by the primary amine group in the compound acting on the binding pocket. Subsequently, the researchers further evaluated lolamicin's in vivo efficacy in sepsis and acute pneumonia infection models. They found that lolamicin...

This publication has 8 references indexed in Scilit: